中文摘要：

确定预测PD-1/PD-L1通路阻断治疗临床反应的生物标志物有助于患者筛查和个体化治疗.研究证明治疗前肿瘤组织中肿瘤细胞和肿瘤浸润淋巴细胞PD-L1的高表达,肿瘤间CD8＋T细胞的大量浸润以及肿瘤细胞基因高突变负荷的患者阻断PD-1/PD-L1通路治疗的临床疗效更明显,这些生物标志物有望成为筛查肿瘤患者的指标.

英文摘要：

Identifying biomarkers predicting clinical response to treatment of PD-1/PD-L1 pathway blockade can guide patient selection and therapeutic individualization.Some researches have shown that patients with cancer will acquire better clinical effects by blocking PD-1/PD-L1 pathway whose characteristics include higher pretreatment expression of PD-L1 by tumor cells or tumor infiltrating immune cells,the massive infiltration of intratumoral CD8 ＋ T cells,the high mutation frequency of tumor cell gene.These biomarkers are expected to become indicators which can select patients.